Skip to content

13F-HR filed by Prosight Management, LP

Prosight Management, LP filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-13, with 29 holding rows worth $135,969,000.

Accession
0001420506-18-000189
Filed
2018-02-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2017

A holdings report, 29 entries on the cover page, a total value of $135,969,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $135,969,000 with VALUE read as thousands by filing date, 13F file number 028-18450. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALLERGAN PLCG0177J108SHS98,000$16,031,000thousands by filing date
MACROGENICS INC556099109COM607,696$11,546,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock1,647,879$11,206,000thousands by filing date
EIGER BIOPHARMACEUTICALS INC28249U105COM678,793$9,469,000thousands by filing date
SABRA HEALTH CARE REIT INC COM78573L106REIT402,057$7,547,000thousands by filing date
CENTENE CORP DEL COM15135B101Stock71,000$7,162,000thousands by filing date
CHIMERIX INC COM16934W106Stock1,478,519$6,846,000thousands by filing date
ACHAOGEN INC004449104COM570,920$6,132,000thousands by filing date
UNIQURE NVN90064101SHS284,717$5,578,000thousands by filing date
ALMOST FAMILY INC020409108COM90,548$5,012,000thousands by filing date
REATA PHARMACEUTICALS INC75615P103CL A172,897$4,896,000thousands by filing date
QUOTIENT LTDG73268107SHS932,523$4,616,000thousands by filing date
IGNYTA INC451731103COM171,352$4,575,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM506,852$4,055,000thousands by filing date
ENDOLOGIX INC29266S106COM655,815$3,509,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW110,000$3,495,000thousands by filing date
PARATEK PHARMACEUTICALS INC699374302Equity178,453$3,194,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM1,057,690$2,951,000thousands by filing date
NABRIVA THERAPEUTICS PLCG63637105SHS491,395$2,939,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM40,000$2,720,000thousands by filing date
BELLICUM PHARMACEUTICALS INC079481107COM301,349$2,534,000thousands by filing date
ULTRAGENYX PHARMACEUTICAL IN90400D108COM44,600$2,069,000thousands by filing date
DEXCOM INC COM252131107Stock31,198$1,790,000thousands by filing date
ON ASSIGNMENT INC682159958COM25,700$1,652,000thousands by filing dateput
LIPOCINE INC NEW53630X104CMN373,101$1,283,000thousands by filing date
CONFORMIS INC20717E101COM400,000$952,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW296,488$925,000thousands by filing date
ACADIA HEALTHCARE COMPANY INC COM00404A109Stock26,916$878,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM12,000$407,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-18-000189this filing2018-02-13acceptance time not in the bulk data set